Therapeutics News and Research

RSS

Researchers identify novel viral sensor complex

Double-stranded (ds) RNA viruses are a diverse group of viruses that include rotaviruses, a common cause of gastroenteritis. The ability of the immune system to detect and destroy viruses is critical for human health and survival.

24 Jun 2011

AMT receives CHMP opinion on Glybera Marketing Authorisation Application

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.

24 Jun 2011

Hunger hormone likely to cause stress-linked complex eating behaviors

We are one step closer to deciphering why some stressed people indulge in chocolate, mashed potatoes, ice cream and other high-calorie, high-fat comfort foods. UT Southwestern Medical Center-led findings, in a mouse study, suggest that ghrelin - the so-called "hunger hormone" - is involved in triggering this reaction to high stress situations.

24 Jun 2011

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Arno Therapeutics, Inc. announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with Avastin and will continue toward completion.

23 Jun 2011

Axxam receives ADDF grant to develop new therapeutics for Alzheimer's

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant to Axxam SpA to develop small molecules to treat Alzheimer's disease by targeting inflammation.

23 Jun 2011

Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection

Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).

22 Jun 2011

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

22 Jun 2011

UC Riverside research could lead to novel therapeutics for epileptic seizures

Researchers at the University of California, Riverside have made a discovery in the lab that could help drug manufacturers develop new antiepileptic drugs and explore novel strategies for treating seizures associated with epilepsy - a disease affecting about two million Americans.

22 Jun 2011

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis.

22 Jun 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a U.S. patent relating to a technology for the treatment of cancer for which the Company holds an exclusive, worldwide license.

22 Jun 2011

Scientists discover molecular mechanism that could help develop new MS treatments

Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) — a chronic inflammatory disease of the central nervous system.

22 Jun 2011

Seaside Therapeutics commences STX209 Phase 2b study in autism spectrum disorders

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 2b study to evaluate the effects of STX209 (arbaclofen) on social impairment in children, adolescents and adults with autism spectrum disorders.

21 Jun 2011

Respira reports results of DPI drug engine clinical study against COPD, asthma

Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.

21 Jun 2011

Halozyme to present three data on Ultrafast Insulin programs at ADA 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.

21 Jun 2011

Benitec’s pain program validated by independent study

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, announced that China-based researchers have proved the concept behind Benitec's in house neuropathic pain program.

20 Jun 2011

Genomic study identifies MCU that regulates calcium transport into mitochondria

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Massachusetts General Hospital (MGH), the Broad Institute, and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), today announced new findings published in Nature.

20 Jun 2011

Patients still being enrolled in clinical trial for new peripheral vascular disease treatment

The first three patients to undergo an investigational surgical procedure for peripheral vascular disease that involves the patient's own stem cells continue to do well, reports the University of Louisville surgeon who is the principal investigator.

18 Jun 2011

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

17 Jun 2011

Innovative adult stem cell approach could help eliminate obesity

Innovative adult stem cell research by scientists at The University of Texas Health Science Center at Houston could aid efforts to apply the brakes to stem cells that produce the type of fat ringing the waists of millions. Research appeared today online ahead of the print issue of Cell Stem Cell.

17 Jun 2011

Therapeutics News and Research

Researchers identify novel viral sensor complex

AMT receives CHMP opinion on Glybera Marketing Authorisation Application

Hunger hormone likely to cause stress-linked complex eating behaviors

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Axxam receives ADDF grant to develop new therapeutics for Alzheimer's

Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

UC Riverside research could lead to novel therapeutics for epileptic seizures

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

Scientists discover molecular mechanism that could help develop new MS treatments

Seaside Therapeutics commences STX209 Phase 2b study in autism spectrum disorders

Respira reports results of DPI drug engine clinical study against COPD, asthma

Halozyme to present three data on Ultrafast Insulin programs at ADA 2011

Benitec’s pain program validated by independent study

Genomic study identifies MCU that regulates calcium transport into mitochondria

Patients still being enrolled in clinical trial for new peripheral vascular disease treatment

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Innovative adult stem cell approach could help eliminate obesity

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News